DPA
RCKT icon

Devon Park Associates’s Rocket Pharmaceuticals RCKT Stock Holding History

Devon Park Associates’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$30.8M Hold
810,927
– – 100% 1
2016
Q2 		$24.1M Hold
810,927
– – 100% 1
2016
Q1 		$24M Hold
810,927
– – 100% 1
2015
Q4 		$36.8M Hold
810,927
– – 100% 1
2015
Q3 		$30.5M Hold
810,927
– – 15.27% 2
2015
Q2 		$15.9M Hold
810,927
– – 10.53% 2
2015
Q1 		$17.6M Buy
+810,927
New +$19M 12.95% 2

Other funds holding RCKT

RCP
Rho Capital Partners New York $20.4M AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Devon Park Associates's RCKT Position: Q3 2016 in Review

Devon Park Associates held its Rocket Pharmaceuticals (RCKT) position steady in Q3 2016 at 810,927 shares worth $30.8M. The position accounts for 100% of the portfolio, ranked #1.

Devon Park Associates first reported a position in RCKT in Q1 2015 and has held it in 7 quarters since. The position peaked at $36.8M in Q4 2015. 78 funds tracked by Wall St. Rank hold RCKT as of Q3 2016.

  • Devon Park Associates held 810,927 shares of Rocket Pharmaceuticals worth $30.8M as of Q3 2016.
  • Devon Park Associates left its Rocket Pharmaceuticals share count unchanged in Q3 2016.
  • Rocket Pharmaceuticals made up 100% of Devon Park Associates's portfolio in Q3 2016, its #1 holding.
  • Devon Park Associates first reported a position in Rocket Pharmaceuticals in Q1 2015 and has held it in 7 quarters since.
  • Devon Park Associates's Rocket Pharmaceuticals position peaked at $36.8M in Q4 2015.
  • 78 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2016.

Based on Devon Park Associates's 13F filing for Q3 2016, filed 14 Nov 2016.